Introduction
============

Amaryllidaceae alkaloids have long attracted the attention of synthetic chemists due to their significant bioactivities such as antitumor, antiviral, and anti-acetylcholinesterase activities, and the fascinating diversity of their structures. To date, more than 500 Amaryllidaceae alkaloids have been isolated from Amaryllidaceae plants.^[@cit1]^ However, only one member of them, galanthamine, has been approved as a prescription drug for the treatment of Alzheimer's disease.^[@cit2]^ Because these alkaloids are structurally intricate, general methods for their synthesis are lacking, which has hindered the study of their medicinal chemistry.

We recently became particularly interested in crinine-type alkaloids, a large subclass (more than 80 have been isolated) of the Amaryllidaceae alkaloid family, that possess an antipodal chiral 5,10*b*-ethanophenanthridine core skeleton with a benzylic all-carbon quaternary centre^[@cit1c]^ ([Fig. 1](#fig1){ref-type="fig"}). For example, the parent alkaloid of the subclass, (--)-crinine, was first isolated in 1955 from the bulbs of two unidentified *Crinum* species from South Africa;^[@cit3]^ (+)-vittatine, which has the opposite configuration to that of (--)-crinine, is another crinine-type alkaloid.^[@cit4]^ Importantly, the crinine-type alkaloids are considered to be biogenic precursors of several types of Amaryllidaceae alkaloids including tazettine-, haemanthamine-, and narciclasine-type alkaloids^[@cit5]^ ([Fig. 1](#fig1){ref-type="fig"}). Thus, exploring efficient methods for the rapid synthesis of diverse crinine-type alkaloids is particularly important and desirable. However, although great efforts have been devoted to the development of synthetic methods to obtain crinine-type alkaloids, most of the reported approaches provided racemic products.^[@cit6]^

![Representative crinine-type alkaloids and Amaryllidaceae alkaloids derived possibly from crinine-type alkaloids.](c7sc02112g-f1){#fig1}

We noticed that some Amaryllidaceae species can produce two similar alkaloids with enantiomeric skeletons. For example, both (--)-crinine and (+)-epivittatine have been isolated simultaneously from the bulbs of *Nerine bowdenii*, *Boophane flava*, and *Crinum moorei* ([Scheme 1a](#sch1){ref-type="fig"}).^[@cit4b],[@cit9]^ Inspired by this natural phenomenon and the biosynthetic pathway of crinine-type alkaloids, we envisaged a new synthetic strategy that mimics the enzymatic reduction resolution of racemic oxocrinines **1** using synthetic chiral catalysts ([Scheme 1b](#sch1){ref-type="fig"}). Because racemic oxocrinines **1** can be prepared in only four steps in high yields by a biomimetic intramolecular phenolic oxidative coupling of *O*-methylnorbelladine derived from [l]{.smallcaps}-phenylalanine and [l]{.smallcaps}-tyrosine,^[@cit6f]^ this asymmetric catalytic stereodivergent resolution strategy^[@cit10]^ will provide a concise and rapid approach to diverse crinine-type alkaloids and their analogues.

![Possible biosynthetic process of crinine-type alkaloids and our envisaged bioinspired strategy.](c7sc02112g-s1){#sch1}

Results and discussion
======================

Although asymmetric hydrogenation of the ketone group of α,β-unsaturated ketones is an efficient way for synthesising optically active allylic alcohols,^[@cit11]^ the asymmetric hydrogenation of cyclohexenones with no substituent at the α-position is still a challenge ([Scheme 1c](#sch1){ref-type="fig"}).^[@cit12]^ To find efficient chiral catalysts for the asymmetric hydrogenation of racemic oxocrinines **1**, we investigated chiral spiro iridium catalysts Ir-SpiroPAP (**3**)^[@cit13]^ developed in our laboratory. The racemic oxocrinines **1** were prepared in four steps with 55--66% yield from commercially available starting materials using Node's biomimetic procedure^[@cit6f]^ (see the ESI[†](#fn1){ref-type="fn"}). Asymmetric hydrogenation of *rac*-**1a** (R^1^, R^2^ = --CH~2~--, R^3^, R^4^ = H) was firstly carried out using the catalyst (*R*)-**3a**. When the hydrogenation of *rac*-**1a** was performed under 1 atm of H~2~ pressure with KO*t*Bu as the base in EtOH at room temperature, the reaction was completed within 0.8 h and the desired products (--)-*cis*-**2a** and (+)-*trans*-**2a** were obtained in 91% yield with a (--)-*cis*-**2a**/(+)-*trans*-**2a** ratio of 11 : 88. However, the enantiomeric excess (ee) of the major product (+)-*trans*-**2a** was only 27% ([Table 1](#tab1){ref-type="table"}, entry 1). A comparison of the various Ir-SpiroPAP catalysts showed that (*R*)-**3d**, containing P(3,5-di-*tert*-butylphenyl)~2~ groups and a 3-Me--pyridine moiety, is the best catalyst, which afforded the products (--)-*cis*-**2a** and (+)-*trans*-**2a** in 93% yield with 97% ee and 87% ee, respectively, in a ratio of 45 : 55 (entry 4). The effect of solvent was examined, and *n*PrOH gave comparable results to EtOH (entry 8). In addition to KO*t*Bu, other bases such as KOH, K~2~CO~3~ and Et~3~N can also be used, although the reaction with Et~3~N needs a longer time for completion and the yield is lower (entry 11). Further study of the reaction temperature, base concentration, hydrogen pressure, and co-solvent established the optimal reaction conditions to be as follows: 0.1 mol% (*R*)-**3d**, \[*rac*-**1a**\] = 0.17 M, \[KO*t*Bu\] = 0.008 M, 0 °C, 1 atm of H~2~, EtOH/DCM (5 : 2). Under these conditions, hydrogenation of *rac*-**1a** afforded two crinine-type alkaloids: (--)-*cis*-**2a** (crinine, 97% ee) and (+)-*trans*-**2a** (epivittatine, 93% ee) in 94% overall yield with a (--)-*cis*-**2a**/(+)-*trans*-**2a** ratio of 46 : 54 (entry 16). It is to be noted that we have tried the direct isolation of the mixture of (--)-*cis*-**2a** and (+)-*trans*-**2a** by chromatography on a Sephadex LH-20 column according to Codina's protocol,^[@cit14]^ but it was demonstrated to be difficult. Fortunately, we found that the mixture can be isolated by converting them into benzoyl esters, and after hydrolysis of the isolated benzoyl esters (--)-*cis*-**2a** and (+)-*trans*-**2a** can be obtained in pure form with high yield.

###### Optimization of the reaction conditions for the asymmetric hydrogenation of *rac*-**1a** [^*a*^](#tab1fna){ref-type="fn"}

  ![](c7sc02112g-u1.jpg){#ugr1}                                                                             
  ------------------------------------------ -------------- --------- ----------- ----- ---- --------- ---- ----
  1                                          (*R*)-**3a**   EtOH      KO*t*Bu     0.8   91   11 : 88   90   27
  2                                          (*R*)-**3b**   EtOH      KO*t*Bu     0.5   89   15 : 85   88   23
  3                                          (*R*)-**3c**   EtOH      KO*t*Bu     0.8   95   46 : 54   90   86
  4                                          (*R*)-**3d**   EtOH      KO*t*Bu     0.5   93   45 : 55   97   87
  5                                          (*R*)-**3e**   EtOH      KO*t*Bu     1.0   90   42 : 58   91   77
  6                                          (*R*)-**3f**   EtOH      KO*t*Bu     0.3   95   36 : 64   94   64
  7                                          (*R*)-**3d**   MeOH      KO*t*Bu     0.7   92   40 : 60   92   76
  8                                          (*R*)-**3d**   *n*PrOH   KO*t*Bu     0.8   91   43 : 57   95   90
  9                                          (*R*)-**3d**   EtOH      KOH         0.3   90   46 : 54   95   87
  10                                         (*R*)-**3a**   EtOH      K~2~CO~3~   0.5   91   46 : 54   95   87
  11                                         (*R*)-**3d**   EtOH      Et~3~N      19    79   38 : 62   90   90
  12[^*e*^](#tab1fne){ref-type="table-fn"}   (*R*)-**3d**   EtOH      KO*t*Bu     0.3   90   44 : 56   99   85
  13[^*f*^](#tab1fnf){ref-type="table-fn"}   (*R*)-**3d**   EtOH      KO*t*Bu     3     93   46 : 54   98   88
  14[^*g*^](#tab1fng){ref-type="table-fn"}   (*R*)-**3d**   EtOH      KO*t*Bu     7.5   91   46 : 54   94   88
  15[^*h*^](#tab1fnh){ref-type="table-fn"}   (*R*)-**3d**   EtOH      KO*t*Bu     9     89   46 : 54   99   90
  16[^*i*^](#tab1fni){ref-type="table-fn"}   (*R*)-**3d**   EtOH      KO*t*Bu     8.5   94   46 : 54   97   93

^*a*^Reaction conditions: 1 mmol scale, \[**1a**\] = 0.17 M, 0.1 mol% of (*R*)-**3**, \[base\] = 0.017 M, solvent (6.0 mL), 1 atm of H~2~, room temperature (22--27 °C), 100% conversion.

^*b*^Isolated yield of the mixture of (--)-*cis*-**2a** and (+)-*trans*-**2a**.

^*c*^The ratio of *cis* to *trans* was determined by ^1^H NMR.

^*d*^The ee values of (--)-*cis*-**2a** and (+)-*trans*-**2a** were determined by chiral HPLC (Chiralcel OD-3 column) after converting them into benzoyl esters.

^*e*^Under 5 atm of H~2~.

^*f*^At 0 °C.

^*g*^At 0 °C, and \[KO*t*Bu\] = 0.034 M.

^*h*^At 0 °C, and \[KO*t*Bu\] = 0.008 M.

^*i*^At 0 °C, \[KO*t*Bu\] = 0.008 M, and DCM as co-solvent (ethanol/DCM = 5 : 2).

Using this bioinspired asymmetric hydrogenation stereodivergent resolution method, a range of crinine-type alkaloids and analogues were synthesized from the corresponding racemic oxocrinines **1** ([Table 2](#tab2){ref-type="table"}). In each reaction, two crinine-type alkaloids or analogues were obtained in high yield with high enantioselectivity. The absolute configurations of the products were determined by the configuration of the catalyst.

###### Asymmetric syntheses of crinine-type alkaloids and analogues by hydrogenation of *rac*-**1** catalyzed by (*R*)-**3d** and (*S*)-**3d** [^*a*^](#tab2fna){ref-type="fn"}

  -------------------------------
  ![](c7sc02112g-u2.jpg){#ugr2}
  -------------------------------

^*a*^Reaction conditions: 1 mmol scale, \[**1**\] = 0.17 M, 0.1 mol% of (*R*)-**3d** or (*S*)-**3d**, \[KO*t*Bu\] = 0.008 M, EtOH/DCM (5 : 2, 6.0 mL), 1 atm H~2~, 0 °C, 100% conversion. The *cis*/*trans* ratio was determined by ^1^H NMR. The products were obtained by converting them into benzoyl esters, followed by chromatography on silica gel and hydrolysis of the resulting isolated products with NaOH aqueous solution. The ee values of the products were determined by chiral HPLC analysis of the corresponding benzoyl esters. All the yields are isolated yields.

The Ir-SpiroPAP-catalyzed asymmetric hydrogenation of oxocrinines **1** could be performed on a multigram scale ([Scheme 2](#sch2){ref-type="fig"}). For example, hydrogenation of substrates *rac*-**1a** and *rac*-**1c** on a 2 g scale produced (--)-*cis*-**2a** and (+)-*trans*-**2a**, and (--)-*cis*-**2c** and (+)-*trans*-**2c** in the presence of the catalyst (*R*)-**3d** and produced (+)-*cis*-**2a** and (--)-*trans*-**2a**, and (+)-*cis*-**2c** and (--)-*trans*-**2c** in the presence of the catalyst (*S*)-**3d**, with high yields and high enantioselectivities. After saturation of the C0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 1111111111111111111111111111111111 1111111111111111111111111111111111 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 1111111111111111111111111111111111 1111111111111111111111111111111111 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000C bonds of alkaloids **2a** over Pd/C, four dihydrocrinine-type alkaloids were obtained: (--)-dihydrocrinine,^[@cit15]^ (+)-dihydrovittatine,^[@cit16]^ (+)-dihydroepivittatine,^[@cit17]^ and (--)-dihydroepicrinine.^[@cit17]^ By debenzylation of alkaloids **2c** with boron trichloride (BCl~3~), four naturally occurring crinine-type alkaloids were obtained: (+)-8-*O*-demethylmaritidine,^[@cit18]^ (--)-8-*O*-demethylmaritidine,^[@cit19]^ (+)-siculine,^[@cit16]^ and (--)-siculine.^[@cit20]^

![Asymmetric syntheses of 8-*O*-demethylmaritidines, siculines and dihydrocrinine-type alkaloids on the gram-scale.](c7sc02112g-s2){#sch2}

The methylation of the hydroxy group of the alkaloids **2** can offer *O*-methyl crinine-type alkaloids. When (--)-*cis*-**2a** and (--)-*cis*-**2d** were treated with TMSCH~2~N~2~ (trimethylsilyl diazomethane) in the presence of HBF~4~ in DCM, another two alkaloids, (--)-buphanisine and (--)-buphanidrine,^[@cit21]^ were obtained in 62% and 68% yield, respectively ([Scheme 3](#sch3){ref-type="fig"}). According to Guillou's procedure,^[@cit6j],[@cit22]^ (--)-*trans*-**2a** was successfully oxidized with peroxymidic acid generated *in situ* from CCl~3~CN/H~2~O~2~ to the epoxide **4** in 68% yield in the presence of trifluoroacetic acid. A Mitsunobu reaction converted the epoxide **4** to the benzoate, followed by the removal of the benzoyl group with LiAlH~4~, yielding (--)-flexinine^[@cit23]^ in 60% yield (2 steps). The (--)-flexinine was reacted with TMSCH~2~N~2~ in the presence of HBF~4~ in DCM to produce (--)-augustine in 69% yield. Thus, the enantioselective syntheses of (--)-buphanisine, (--)-buphanidrine, (--)-flexinine, and (--)-augustine were also achieved.

![Asymmetric synthesis of *O*-methyl crinine-type alkaloids and analogues.](c7sc02112g-s3){#sch3}

Conclusions
===========

In conclusion, we have developed a bioinspired strategy for the rapid enantioselective synthesis of crinine-type alkaloids. This strategy features an iridium-catalyzed asymmetric hydrogenation of racemic cycloenones with a remote arylated quaternary stereocenter *via* stereodivergent resolution. Using this new strategy, we synthesized a total of 24 crinine-type alkaloids and 8 analogues in 7.9--29.4% yields in only five or nine steps (seven or eleven steps including the esterification and hydrolysis in the separation of the hydrogenation products). Among these crinine-type alkaloids, seven have been previously synthesized with 8--20 steps in 0.6--13.2% yields (see also ESI[†](#fn1){ref-type="fn"}).^[@cit7],[@cit8]^ Eleven were synthesized for the first time: (+)- and (--)-8-*O*-demethylmaritidine, (+)- and (--)-siculine, (--)-maritidine, (--)-epimaritidine, (+)-powelline, (+)-epipowelline, (--)-buphanidrine, (--)-flexinine and (--)-augustine. The concise, practical strategy reported here for the synthesis of crinine-type alkaloids and analogues is expected to be applicable for the rapid syntheses of other types of Amaryllidaceae alkaloids or even other types of natural products.
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[^1]: †Electronic supplementary information (ESI) available. See DOI: [10.1039/c7sc02112g](10.1039/c7sc02112g) Click here for additional data file.
